Targeting AXL could block the activation of the Gas6/AXL pathway, inhibit the proliferation of AML cells, and overcome the resistance of FLT3-ITD + AML cells to FLT3 inhibitors. The gene discussed is FLT3; the disease is acute myeloid leukemia.